Previous 10 | Next 10 |
home / stock / anvs / anvs articles
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dru...
Immutep Limited (NASDAQ: IMMP) jumped 14.9% after it announced positive results from cohort B of the late-stage TACTI-003 (KEYNOTE-PNC-34) stu...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 millio...
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief ...
Annovis Bio, Inc. (NYSE:ANVS) stock is showing gains during premarket trading on Wednesday, following a significant increase of more than 76% in th...
On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in positive territory, i...
Annovis Bio, Inc (NYSE:ANVS) stock is trending Tuesday. The company eelier announced new data from its Phase III Parkinson’s study. What Happ...
Merck (NYSE: MRK) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP...
News, Short Squeeze, Breakout and More Instantly...
The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12%...
Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of ...
Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food an...